Sulfasalazine and Anesthesia: Perioperative Management
Continue sulfasalazine through the perioperative period without interruption for patients undergoing elective surgery, including total hip or knee arthroplasty. 1
Primary Recommendation
The 2017 ACR/AAHKS guideline explicitly recommends continuing sulfasalazine at the current dose for patients with rheumatic diseases undergoing elective total hip or knee arthroplasty 1. This recommendation extends to general surgical procedures requiring anesthesia.
Evidence Supporting Continuation
- Reduced infection risk: Systematic reviews demonstrate that continuing DMARDs (including sulfasalazine) actually decreases perioperative infection risk, with a relative risk of 0.39 (95% CI 0.17–0.91) compared to discontinuation 1
- Reduced flare risk: Disease flares occur less frequently when sulfasalazine is continued (RR 0.06 [95% CI 0.0–1.10]) 1
- No significant anesthetic interactions: Sulfasalazine does not have clinically significant interactions with anesthetic agents that would necessitate discontinuation 2
Rationale for This Approach
The guideline's recommendation is based on moderate-quality evidence from RCTs comparing continuation versus discontinuation of DMARDs perioperatively. The evidence was rated down from high quality due to indirectness (some studies were from non-orthopedic procedures), but the signal consistently favors continuation 1.
The key principle: Stopping sulfasalazine increases both infection risk (through disease flare and inflammation) and disease activity, without providing any protective benefit 1.
Perioperative Monitoring Considerations
While continuing sulfasalazine, be aware of the drug's known toxicities that require monitoring 3:
- Hematologic: Monitor for signs of agranulocytosis, aplastic anemia, or other blood dyscrasias (sore throat, fever, pallor, purpura)
- Hepatotoxicity: Watch for jaundice or elevated liver enzymes
- Serious infections: Sulfasalazine can predispose to infections, including fatal sepsis and pneumonia, particularly in patients with neutropenia 3
- Hypersensitivity reactions: Discontinue immediately if skin rash, mucosal lesions, or systemic hypersensitivity develops 3
Common Pitfalls to Avoid
- Do not reflexively stop all chronic medications: The outdated practice of discontinuing all DMARDs perioperatively actually increases complications 1
- Do not confuse with biologic DMARDs: Unlike biologics (which should be withheld before surgery), conventional DMARDs like sulfasalazine should be continued 1
- Do not delay surgery for medication washout: There is no need to time surgery around sulfasalazine dosing cycles 1
Practical Implementation
- Verify the patient's current sulfasalazine dose (typical maintenance: 2g daily in adults) 3
- Continue the medication on the morning of surgery with a sip of water
- Resume normal dosing schedule postoperatively as soon as oral intake is tolerated
- Ensure complete blood counts are current given the drug's hematologic risks 3
This recommendation applies to all surgical procedures requiring anesthesia, not just orthopedic surgery, as the underlying principle (balancing infection risk versus disease control) remains consistent across surgical contexts 2.